REDUCE-IT Trial Data Updates: Key Takeaways

Researchers investigated the timing of hypertension diagnosis, exploring how it’s associated with medication prescribing and long-term cardiovascular outcomes.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Patients with a single cardiometabolic disease have an approximate 48% greater risk of developing all-cause dementia compared with those without a cardiometabolic disease.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Investigators of a study used a systematic review and meta-analysis to evaluate the risk of major adverse cardiac events related to cannabis by using real-world data.